The opening portion of SurfingMASH’s April roundtable on drug development looks at developments in the FGF-21 mode of action and, more generally, treatment of patients with cirrhosis, with tremendous enthusiasm.
SurfingMASH kicks off a month of Drug Development stories looking at FGF-21s and the future of therapies for cirrhosis and MASH, plus a paper on real-world resmetirom prescribing.
Maru Rinella, corresponding author for the recent expert panel recommendations on resmetirom, joins the Surfers to discuss key points of the recommendations and the rationale behind them.
Roger Green speaks with SurfingMASH co-host and Tawazun Health Founder and Clinical Director Louise Campbell on the last day of the EASL Congress. Their conversation focuses on how practice patterns, guidelines and training might change over the next few years.
Roger Green speaks with Hepatology Key Opinion Leader and EASL Educational Councillor Sven Francque 90 minutes after the EASL Congress closed. The discussion covers Clinical Practice Guidelines, drug development and NITs.
In this closing conversation, updated MASLD CPG co-authors Frank Tacke and Elisabetta Bugianesi and podcast co-hosts Louise Campbell and Roger Green consider what the guidelines might foretell in changes in provider education, structure of patient visits and treatment in less affluent or medically advanced countries.
For most of this conversation, updated MASLD CPG co-authors Frank Tacke and Elisabetta Bugianesi discuss key issues related to pharmacology and prescribing choices. At the end, the focus shifts to the guidelines’ overall benefits and some new kinds of education they call for.
This conversation covers some of the other major drug development stories from the EASL Congress 2024, with special focus on denifenstat, ION-224 and TAK-227, plus a look at the SPECIAL study on bariatric surgery and cirrhosis.
Roger Green is joined by Sober Livers Founder/Visionary Jenn Jones and Principal Strategic Advisor Beth Lehman to discuss HOPE, (Healing Others with Peers and Education), a support program launching June 11 for people who have harmed their bodies through ALD and its consequences.
Michael Charlton joins the Surfers for a far-reaching conversation, with topics ranging from how his clinic is integrating Rezdiffra in MASH patient treatment to exciting research, both reported and in development.
